BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32850362)

  • 1. High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis.
    Sun X; Wang L; Wang Y; Kang J; Jiang W; Men Y; Hui Z
    Front Oncol; 2020; 10():1222. PubMed ID: 32850362
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of radiation dose on the efficacy of definitive chemoradiotherapy in patients with locally advanced esophageal carcinoma: a systematic review and meta-analysis.
    Luo D; Zhong Q; Zhu X
    Cancer Biol Ther; 2023 Dec; 24(1):1-10. PubMed ID: 36519807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients.
    Kang J; Chang JY; Sun X; Men Y; Zeng H; Hui Z
    J Cancer; 2018; 9(3):584-593. PubMed ID: 29483964
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of modern high-dose versus standard-dose radiation in definitive concurrent chemo-radiotherapy on outcome of esophageal squamous cell cancer: a meta-analysis.
    Luo HS; Huang HC; Lin LX
    Radiat Oncol; 2019 Oct; 14(1):178. PubMed ID: 31623639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: A systematic review and meta-analysis.
    Yao Y; Lu J; Qin Z; Li N; Ma J; Yao N; Qu W; Cui L; Yuan S; Jiang A; Liu X
    Radiother Oncol; 2023 Jul; 184():109700. PubMed ID: 37169302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy and safety of high dose versus standard dose radiotherapy in concurrent chemoradiotherapy for patients with esophageal squamous cell carcinoma].
    Ren XJ; Wang L; Han C; Liu LL
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):135-139. PubMed ID: 30862144
    [No Abstract]   [Full Text] [Related]  

  • 7. High versus standard radiation dose of definitive concurrent chemoradiotherapy for esophageal cancer: A systematic review and meta-analysis of randomized clinical trials.
    Wang X; Bai H; Li R; Wang L; Zhang W; Liang J; Yuan Z
    Radiother Oncol; 2023 Mar; 180():109463. PubMed ID: 36642387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review.
    Xiao L; Czito BG; Pang Q; Hui Z; Jing S; Shan B; Wang J
    J Cancer; 2020; 11(15):4605-4613. PubMed ID: 32489478
    [No Abstract]   [Full Text] [Related]  

  • 9. Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis.
    Wang J; Xiao L; Wang S; Pang Q; Wang J
    Front Oncol; 2021; 11():665231. PubMed ID: 34589418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques.
    Yen YC; Chang JH; Lin WC; Chiou JF; Chang YC; Chang CL; Hsu HL; Chow JM; Yuan KS; Wu ATH; Wu SY
    Cancer; 2017 Jun; 123(11):2043-2053. PubMed ID: 28152166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma.
    Xu YC; Chen KH; Liang ZG; Zhu XD
    Front Oncol; 2022; 12():843675. PubMed ID: 35903695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012.
    Brower JV; Chen S; Bassetti MF; Yu M; Harari PM; Ritter MA; Baschnagel AM
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):985-993. PubMed ID: 27869098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective analysis of safety profile of high-dose concurrent chemoradiotherapy for patients with oesophageal squamous cell carcinoma.
    Ren X; Wang L; Han C; Ren L
    Radiother Oncol; 2018 Nov; 129(2):293-299. PubMed ID: 30270099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A multicenter randomized prospective study of concurrent chemoradiation with 60 Gy versus 50 Gy for inoperable esophageal squamous cell carcinoma].
    Xu YJ; Zhu WG; Liao ZX; Kong Y; Wang WW; Li JC; Huang R; He H; Yang XM; Liu LP; Sun ZW; He HJ; Bao Y; Zeng M; Pu J; Hu WY; Ma J; Jiang H; Liu ZG; Zhuang TT; Tan BX; Du XH; Qiu GQ; Zhou X; Ji YL; Hu X; Wang J; Ma HL; Zheng X; Huang J; Liu AW; Liang XD; Tao H; Zhou JY; Liu Y; Chen M
    Zhonghua Yi Xue Za Zhi; 2020 Jun; 100(23):1783-1788. PubMed ID: 32536123
    [No Abstract]   [Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
    Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent erlotinib and radiotherapy for chemoradiotherapy-intolerant esophageal squamous cell carcinoma patients: results of a pilot study.
    Zhai Y; Hui Z; Wang J; Zou S; Liang J; Wang X; Lv J; Chen B; Zhu H; Wang L
    Dis Esophagus; 2013 Jul; 26(5):503-9. PubMed ID: 22862289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose versus conventional-dose irradiation in cisplatin-based definitive concurrent chemoradiotherapy for esophageal cancer: a systematic review and pooled analysis.
    Song T; Liang X; Fang M; Wu S
    Expert Rev Anticancer Ther; 2015; 15(10):1157-69. PubMed ID: 26235427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern.
    Bao Y; Liu S; Zhou Q; Cai P; Anfossi S; Li Q; Hu Y; Liu M; Fu J; Rong T; Li Q; Liu H
    Radiat Oncol; 2013 Oct; 8():241. PubMed ID: 24139225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.